Institute of Medicine Elects Vermund to Membership
Posted by on Wednesday, October 17, 2012 in News Posts.
Vanderbilt University School of Medicine faculty members, R. Daniel Beauchamp, M.D., chair of the Section of Surgical Sciences, and Sten H. Vermund, M.D., Ph.D., director of the Vanderbilt Institute for Global Health, have been elected into the Institute of Medicine (IOM). Membership in the IOM is one of the highest honors presented to elite physician-scientists who demonstrate outstanding professional achievement and commitment to service.
Beauchamp is the professor of Surgery, Cancer Biology and Cell & Developmental Biology, Surgeon-in-Chief of Vanderbilt University Hospital, deputy director of the Vanderbilt-Ingram Cancer Center (VICC) and a project leader in Vanderbilt’s Gastrointestinal Cancer Specialized Program of Research Excellence (SPORE) grant from the National Institutes of Health (NIH). Beauchamp’s particular research interests include Surgical Oncology.
Dr. Vermund’s research interests include infectious disease control and prevention with a focus on developing countries and underserved areas of the southeastern U.S. Dr. Vermund’s impact in the field of biomedical research and medical education reaches far beyond Vanderbilt. Over a span of 30 years, his contributions in infectious disease, epidemiology, women’s and children’s health, and global health have been published in more than 300 peer-reviewed journals. Dr. Vermund has mentored many trainees throughout the world and demonstrated his commitment to HIV/AIDS research by establishing two HIV prevention, care and treatment organizations in Africa.
“Election to membership by one’s peers acknowledges the body of work my colleagues and I have done in global health,” said Vermund, the Amos Christie Chair in Global Health and professor of Pediatrics, Preventive Medicine, Medicine and Obstetrics & Gynecology. “I’m honored to share this recognition with my global and Vanderbilt collaborators.”
In 2012, Dr. Vermund served as principal investigator of the HIV Prevention Trials Network (HPTN) during which time the HPTN 052 protocol was named as the scientific breakthrough of the year for its discoveries of the prevention utility of antiretroviral therapy by Science magazine. Dr. Vermund’s election places him in IOM membership with his colleague, Dr. Myron Cohen, the HPTN 052 Protocol Chair and newly appointed co-principal investigator of HPTN.